- Report
- March 2024
- 195 Pages
Global
From €3242EUR$3,374USD£2,772GBP
€3602EUR$3,749USD£3,080GBP
- Report
- October 2023
- 180 Pages
Global
From €4708EUR$4,900USD£4,025GBP
- Report
- April 2023
- 115 Pages
Global
From €4564EUR$4,750USD£3,902GBP
- Report
- November 2022
- 159 Pages
Global
From €3363EUR$3,500USD£2,875GBP
- Report
- November 2021
- 656 Pages
Global
From €4804EUR$5,000USD£4,107GBP
- Report
- November 2021
- 844 Pages
Global
From €4804EUR$5,000USD£4,107GBP
Prions are proteins that can cause a range of neurological diseases, including Creutzfeldt-Jakob disease (CJD) and mad cow disease. Prions are responsible for a number of neurological disorders, including dementia, seizures, and motor neuron diseases. As such, they are a major focus of research and development in the field of central nervous system drugs.
The prion market is driven by the need to develop treatments for these diseases, as well as to develop diagnostic tests to detect them. Prion-based drugs are being developed to treat a range of neurological disorders, including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). Additionally, research is being conducted to develop vaccines to prevent prion-related diseases.
The prion market is highly competitive, with a number of companies involved in the development of prion-based drugs and diagnostics. These include Biogen, AbbVie, Merck, Pfizer, and Novartis. Additionally, a number of smaller companies are involved in the development of prion-based treatments and diagnostics. Show Less Read more